Caxton Corp lifted its stake in shares of Rezolute, Inc. (NASDAQ:RZLT – Get Rating) by 17.6% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,403,157 shares of the company’s stock after purchasing an additional 209,684 shares during the quarter. Rezolute accounts for 6.1% of Caxton Corp’s holdings, making the stock its 6th biggest holding. Caxton Corp owned approximately 4.18% of Rezolute worth $4,532,000 as of its most recent filing with the SEC.
Other large investors also recently modified their holdings of the company. Provence Wealth Management Group bought a new stake in shares of Rezolute during the 1st quarter worth $68,000. AIGH Capital Management LLC lifted its position in shares of Rezolute by 58.7% during the 1st quarter. AIGH Capital Management LLC now owns 420,913 shares of the company’s stock worth $1,423,000 after buying an additional 155,732 shares during the last quarter. Vanguard Group Inc. lifted its position in shares of Rezolute by 3.2% during the 1st quarter. Vanguard Group Inc. now owns 343,739 shares of the company’s stock worth $1,162,000 after buying an additional 10,500 shares during the last quarter. State Street Corp bought a new stake in shares of Rezolute during the 1st quarter worth $69,000. Finally, Worth Venture Partners LLC lifted its position in shares of Rezolute by 72.5% during the 1st quarter. Worth Venture Partners LLC now owns 104,709 shares of the company’s stock worth $354,000 after buying an additional 43,991 shares during the last quarter. 73.08% of the stock is owned by institutional investors and hedge funds.
Analysts Set New Price Targets
Several brokerages recently weighed in on RZLT. Jefferies Financial Group started coverage on Rezolute in a research report on Monday, September 12th. They set a “buy” rating and a $11.00 price objective for the company. JMP Securities restated a “buy” rating and set a $8.00 price objective on shares of Rezolute in a research report on Friday, September 16th. Four analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $15.17.
Rezolute Stock Performance
Rezolute (NASDAQ:RZLT – Get Rating) last released its earnings results on Thursday, September 15th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.34) by ($0.03). On average, analysts predict that Rezolute, Inc. will post -1.11 EPS for the current year.
Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.
- Get a free copy of the StockNews.com research report on Rezolute (RZLT)
- Are the Short Sellers Still Right About Mullen Automotive stock?
- La-Z-Boy Reclines To More Comfortable Levels
- Is Apple Going To Rally Into Year End?
- Is The Recovery Rally Here For SoFi?
- Will Easing Of Covid Rules Slash Risk For Chinese EV Maker NIO?
Receive News & Ratings for Rezolute Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rezolute and related companies with MarketBeat.com's FREE daily email newsletter.